Day: August 20, 2020

Company Announcement Kesimpta® (ofatumumab) approved by U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adultsFirst B-cell therapy that can be self-administered using Sensoready® autoinjector penApproval based on Phase III ASCLEPIOS I and II studiesCopenhagen, Denmark; August 20, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of Kesimpta® (ofatumumab) injection for subcutaneous use, for the treatment of relapsing forms of multiple sclerosis (RMS) in adults, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Kesimpta is the first B-cell therapy that can be self-administered by patients at home using the Sensoready® autoinjector pen, once monthly after starting therapy. It is being...

Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple sclerosis (RMS)1 Approval based on two Phase III ASCLEPIOS studies demonstrating significant reductions in risk of relapses, confirmed disability progression, Gd+ T1 brain lesions and new/enlarging T2 lesions1 Kesimpta may halt new disease activity in RMS patients as shown in a post hoc analysis, with 47.0% and 87.8% of patients treated with ofatumumab achieving no evidence of disease activity (NEDA-3) within the first (0–12 months) and second year (12–24 months) of treatment, respectively2The digital press release with multimedia content can be accessed here:Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration...

WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a leader in cloud-based digital experience software, announced today that a major US drop shipping supplier has selected Celebros Search by Bridgeline to enhance the site search capabilities of its online store and improve their customer experience.The Company provides a platform for resellers to access more than 20,000 organic, specialty, and gourmet products online. Major eCommerce platforms such as WooCommerce and Shopify can import products from their website to be delivered directly to consumers. These products are shipped from the Company’s facilities in Los Angeles, Pennsylvania, and Dallas Fort-Worth.The Company found Celebros through Magento, an eCommerce provider and longtime partner to Bridgeline. After a demo of Celebros, the Company...

NEW HAVEN, Conn., Aug. 20, 2020 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has signed an exclusive global distribution agreement with ADS Biotec for the sale and distribution of its proprietary IV-Cell cytogenetics cell culturing media. The companies recently completed the development and have fully validated new version of its media, a next-generation improved product that will yield increased benefits over its first version. Both companies have developed an ambitious go-to-market strategy that will be launched next month, and will be joining forces to rapidly bring the product to market, introducing it to the top major labs worldwide.ADS, and its Japanese parent company ADSTEC, are a worldwide market leader in developing, manufacturing and distributing the HANABI™ cytogenetics...

LEESBURG, Va., Aug. 20, 2020 (GLOBE NEWSWIRE) — Quantum Computing Inc. (OTCQB: QUBT) (QCI), a technology leader in quantum-ready applications and tools, and only public pure play in the quantum computer space, now offers simplified access to several of the world’s top quantum computers (QCs) with its industry-leading Mukai™ software development and execution platform.QCI is the first company with a quantum software development and execution platform to provide the widest selection of QCs via the cloud, including those offered by IonQ, D-Wave, IBM, Rigetti, and others.The same high-level constrained-optimization interface Mukai provides for running applications using its state-of-the-art classical solver can now be used to solve problems on a range of quantum computers, but without any program changes or setting up individual accounts...

Leverkusen, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) — On August 18, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) announced the successful placement of the 1.00% qualified subordinated mandatory convertible bond 2020/2021 with gross proceeds of EUR 7.9 million. Within the scope of the issuance, 2,638,150 qualified subordinated mandatory convertible bearer bonds (the “Bond”) were issued. The subscription price equaled 100% of the nominal value, corresponding to EUR 3.00 per Bond.The mandatory convertible bond 2020/2021, with the German Securities Identification Number A3E454 / ISIN DE000A3E4548, matures on December 20, 2021 and has been admitted for trading on the Open Market of the Frankfurt Stock Exchange as of today, August 20, 2020.According to Section 8 (2) of the terms and conditions of the...

Rekstrartekjur samstæðunnar á öðrum árfjórðungi voru 60,3 m€ og 133,1 m€ á fyrri árshelmingi (2F 2019: 49,6 m€, 1H 2019: 105,5 m€).  Aukningu rekstrartekna má fyrst og fremst rekja til þess að sölufélög í Asíu eru hluti af samstæðunni í ár, en félögin eru hluti af samstæðureikningsskilum Brims frá 1. október 2019.  Rekstrartekjur sölufélaganna, að teknu tilliti til innbyrðis viðskipta námu 25 m€ á öðrum ársfjórðungi og 45 m€ á fyrri árshelmingi 2020.EBITDA nam 9,5 m€ á öðrum ársfjórðungi og 17,2 m€ á fyrri árshelmingi (2F 2019: 13,3 m€, 1H 2019: 23,1 m€)Hagnaður á öðrum ársfjórðungi var 5,0 m€ og hagnaður á fyrri árshelmingi 5,4 m€ (2F 2019 6,8 m€ hagnaður, 1H 2019: 10,7m€ hagnaður)Handbært fé frá rekstri nam 18,9 m€ á fyrri árshelmingi (1H 2019: 31,1 m€)Fiskvinnslan Kambur ehf., Grábrók ehf. og Grunnur ehf. eru hluti af samstæðunni frá...

Not for Distribution to U.S. Newswire Services or Dissemination in the United StatesVANCOUVER, British Columbia, Aug. 20, 2020 (GLOBE NEWSWIRE) — Aldebaran Resources Inc. (“Aldebaran” or the “Company”, ALDE TSX.V) announces that it intends to complete a non-brokered private placement offering (the “Offering”) for aggregate proceeds of up to $3,000,000 through the issuance of 10,000,000 units of the Company (the “Units”) at a price of $0.30 per Unit. Each Unit will consist of one common share (“Common Share”) in the capital of the Company and one-half of one warrant (each whole warrant, a “Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share at a price of $0.70 until the second anniversary of the closing date of the Offering (the “Expiry Date”).The Company’s two largest shareholders,...

West Palm Beach, FL, Aug. 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Ethema Health Corporation (OTCPINK: GRST) (“Ethema” “GRST” or the “Company”) last reported on July 2, 2020 on its progress with its filing status and its debt restructuring. The Company announces today that it has completed its debt restructuring with Leonite Capital LLC (“Leonite”), including the completion of the additional new financing that was a condition of the restructuring.  The Company has amended the terms of its debt with Leonite to convert over $1.4 million of defaulted debt into CDN$960,000 (approximately US$700,000) of 10% convertible preferred shares in its wholly owned subsidiary Cranberry Cove Holdings Ltd., and $400,000 in 6% convertible preferred shares in the Company.  The Company has filed article of amendment to create a new class...